Query context,Keyword (count),Document Type | Title | Tagged Sentence,Curation,Document Link
overactive_bladder NWSLTR_cooccurence,"oxybutynin (1), oxybutynin hydrochloride (1)","Evaluate News | Evaluate_2020-08-04_Filing | headline: notification of approval for manufacturing and marketing approval of oablok patch in thailand transdermal, overactive bladder treatment patch  source: press release company: hisamitsu pharmaceutical date: july 21, 2020  content: hisamitsu pharmaceutical co., inc. head office: tosu city, saga prefecture, japan; president and ceo: kazuhide nakatomi, hereinafter referred to as hisamitsu pharmaceutical announces that it has obtained approval of manufacturing and marketing for oablok patch generic name: <span style=""background-color: #FFFF00"">oxybutynin</span> hydrochloride, hereinafter referred to as the product in thailand.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/evaluate_email!!!2020-08-04!!!Evaluate_76_2020-08-04_HTML_Extract_12_Filing_&_Registration_News.html"">Evaluate_2020-08-04_Filing"
overactive_bladder NWSLTR_cooccurence,"vibegron (4), URO-902 (1)","press_release | Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results | Business Wire | ... urovant's second product candidate, <span style=""background-color: #FFFF00"">uro 902</span>, is a novel gene therapy being developed for patients with oab who have failed oral pharmacologic therapy.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_12_00_RSS!!!BusinessWire_PR12_06-08-2020_12_00.html"">Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results | Business Wire"
overactive_bladder NWSLTR_cooccurence,vibegron (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">vibegron</span> kyorin pharmaceutical urovant sciences 800031896  type: trial update date: 11 may 2020  content: sinovant sciences plans a phase i trial in volunteers for overactive bladder in china po chictr2000032082 updated 04 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_160_2020-08-04_pharma&biotech_drugs_trial_update_155.html"">AdisInsight_2020-08-04_pharma&biotech"
overactive_bladder NWSLTR_cooccurence,"tolterodine (6), tolterodine tartrate (6)","google_news | Unichem Laboratories gets USFDA nod to market generic version of tolterodine tartrate tablets | unichem laboratories gets usfda nod to market generic version of <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets the news scroll 06 august 2020 last updated at 3 44 pm source pti unichem laboratories gets usfda nod to market generic version of <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets outlook august 06, 2020 15 44 ist unichem laboratories gets usfda nod to market generic version of <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets outlookindia.com 1970 01 01t05 30 00 0530 new delhi, aug 6 pti unichem laboratories ltd on thursday said it has received approval from the us health regulator to market its generic version of <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets used in the treatment of overactive urinary bladder.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_10_15_RSS!!!Google_Search_Urge%20urinary%20incontinence_PR0_06-08-2020_10_15.html"">Unichem Laboratories gets USFDA nod to market generic version of tolterodine tartrate tablets"
overactive_bladder NWSLTR_cooccurence,"tolterodine (5), tolterodine tartrate (5)","google_news | Unichem Laboratories Ltd receives ANDA approval for Tolterodine Tartrate Tablets - EquityBulls.com | unichem laboratories ltd receives anda approval for <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets equitybulls.com mutual funds commodities research tax planning ipo our team contact us follow @equitybulls stock report more unichem laboratories ltd receives anda approval for <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets posted on 2020 08 06 06 08 07 unichem laboratories limited has received anda approval for its <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets, usp 1 mg and 2 mg from the united states food and drug administration usfda to market a generic version of detrol <span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets of pfizer inc.<span style=""background-color: #FFFF00"">tolterodine</span> tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_13_15_RSS!!!Google_Search_Urge%20urinary%20incontinence_PR1_06-08-2020_13_15.html"">Unichem Laboratories Ltd receives ANDA approval for Tolterodine Tartrate Tablets - EquityBulls.com"
overactive_bladder NWSLTR_cooccurence,botulinum toxin (1),"google_news | Can Botox Injections Treat Depression? - Spark Health MD | ... botox was the first drug in which <span style=""background-color: #FFFF00"">botulinum toxin</span> was used.more than 250 million people around the world suffer from depression and common treatments don't work for nearly 33% of the patients, even if they follow their treatment plans, according to who.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!31-07-2020_20_00_RSS!!!Google_Search_Overactive%20bladder_PR0_31-07-2020_20_00.html"">Can Botox Injections Treat Depression? - Spark Health MD"
endometriosis_ NWSLTR_cooccurence,linzagolix (2),"press_release | Home - ObsEva | ... read more our products our pipeline <span style=""background-color: #FFFF00"">linzagolix</span> obe2109 oral gnrh receptor antagonist milestones uterine fibroids maa nda 4q 20 1h 21 primrose 1 positive 24w primary endpoint results july2020 52w results expected 4q 20 primrose 2 positive 24w primary endpoint results dec2019 sustained efficacy and continued safety confirmed at 52w jul2020 76w post treatment follow up period results expected 4q 20 endometriosis initiated phase 3 in 2q 19 positive phase 2b results in 2018 19 commercial rights exclusive worldwide ex asia learn more obe022 oral and selective prostaglandin f2 alpha receptor antagonist milestones phase 2a results in 120 patients expected 2h 20pre clinical phase 1 complete commercial rights exclusive worldwide learn more nolasiban obe001 oral oxytocin receptor antagonist milestones resuming developmentyuyuan bioscience technology prc ind submission 2h 20 in china commercial rights exclusive worldwide ex china partnership with yuyuan bioscience technology prc learn more latest press release obseva announces second quarter 2020 financial results and business update august 6, 2020 primary endpoint successfully met in phase 3 primrose 1 trial of <span style=""background-color: #FFFF00"">linzagolix</span> for the treatment of heavy menstrual bleeding due learn more obseva in the media learn more other obseva press releases learn more work with us are you ready to join an innovative biopharmaceutical company that's advancing women's reproductive health and pregnancy therapeutics currently we have no open vacancies but you can always join our talent community below.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020!!!ObsEva%20SA_PR1_06-08-2020.html"">Home - ObsEva"
endometriosis_ NWSLTR_cooccurence,relugolix (17),"press_release | ene20200806.pdf | ene20200806.pdf myovant sciences announces further financing support from sumitomo dainippon pharma and commercial collaboration with sunovion pharmaceuticals august 5, 2020 usd 200 million low interest, five year term loan commitment from sumitomo dainippon pharma to further support planned commercialization of <span style=""background-color: #FFFF00"">relugolix</span> across multiple indications agreement with sunovion pharmaceuticals provides access to well established commercial infrastructure currently utilized across multiple successful products basel, switzerland, aug. 05, 2020 globe newswire myovant sciences nyse myov , a healthcare company focused on redefining care for women and for men, today announced a usd 200 million low interest, five year term loan commitment from sumitomo dainippon pharma co., ltd. tse 4506 , bringing its total financing support for myovant to usd 600 million, further bolstering myovant's cash and committed funding and increasing the company's financing flexibility as it prepares for multiple potential product launches to treat advanced prostate cancer, uterine fibroids, and endometriosis.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!pdf!!!06-08-2020!!!Sumitomo%20Dainippon%20Pharma%20Co.,%20Ltd._PR1_06-08-2020.pdf"">ene20200806.pdf"
endometriosis_ NWSLTR_cooccurence,relugolix (4),"google_news | Financings for Aug. 5, 2020 | 2020-08-05 | BioWorld | ... additionally, myovant reported it had entered a three year commercial collaboration agreement with sunovion pharmaceuticals inc., an indirect, wholly owned subsidiary of sumitomo dainippon pharma, for services to support the planned commercialization of investigational drug candidate <span style=""background-color: #FFFF00"">relugolix</span>. it will become a nonexclusive distributor of <span style=""background-color: #FFFF00"">relugolix</span> for prostate cancer and the exclusive distributor of <span style=""background-color: #FFFF00"">relugolix</span> combination tablet for uterine fibroids and endometriosis in the u.s. <span style=""background-color: #FFFF00"">relugolix</span> 120 mg is under fda priority review for the treatment of men with advanced prostate cancer, with a target action date of dec. 20, 2020.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!05-08-2020_23_00_RSS!!!Google_Search_Immunic_PR0_05-08-2020_23_00.html"">Financings for Aug. 5, 2020 | 2020-08-05 | BioWorld"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,Treprostinil (2),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">treprostinil</span> patchpump united therapeutics 800040737  type: regulatory status date: 29 jul 2020  content: fda assigns pdufa action date of 27 04 2020 for <span style=""background-color: #FFFF00"">treprostinil</span> patchpump for pulmonary arterial hypertension media release updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_regulatory_status_105.html"">AdisInsight_2020-08-04_pharma&biotech"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,Treprostinil (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: media release  type: regulatory status date: 29 jul 2020  content: united therapeutics corporation announces intention to resubmit nda to the us fda for <span style=""background-color: #FFFF00"">treprostinil</span> patchpump in pulmonary arterial hypertension media release updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_regulatory_status_106.html"">AdisInsight_2020-08-04_pharma&biotech"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,Treprostinil (2),"google_news | Earnings for July 29, 2020 | 2020-07-29 | BioWorld | ... the pulmonary arterial hypertension pah drug remodulin <span style=""background-color: #FFFF00"">treprostinil</span>, intravenous or injected posted a 24% decline from last year, as it faced generic competition. tyvaso <span style=""background-color: #FFFF00"">treprostinil</span>, inhaled for pah outperformed and even matched quarterly revenue from remodulin for the first time, with high single digit growth bringing tyvaso revenue to $119 million, morningstar analyst anna baran said in a report, adding that she expect s tyvaso to be a key part of united's growth story, especially given recent positive data in pulmonary hypertension related to interstitial lung disease.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_23_00_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_29-07-2020_23_00.html"">Earnings for July 29, 2020 | 2020-07-29 | BioWorld"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"Treprostinil (2), treprostinil prodrug (1)","pr_newswire | Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020 | ... insmed's earlier stage clinical pipeline includes brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non cystic fibrosis bronchiectasis and other inflammatory diseases, and <span style=""background-color: #FFFF00"">treprostinil</span> palmitil, an inhaled formulation of a <span style=""background-color: #FFFF00"">treprostinil</span> prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!27-07-2020_12_00_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR10_27-07-2020_12_00.html"">Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,Treprostinil (8),"google_news | Inhaled treprostinil improves QOL, other exploratory outcomes in patients with PAH | inhaled <span style=""background-color: #FFFF00"">treprostinil</span> improves qol, other exploratory outcomes in patients with pah menu all specialties pulmonology all subspecialties all subspecialties more healio jobs account log out log in news cme journals all specialties all specialties aesthetics allergy immunology cardiac vascular intervention cardiology dermatology endocrinology gastroenterology hematology oncology hepatology infectious disease nephrology ophthalmology optometry orthopedics pediatrics primary care psychiatry pulmonology rheumatology all subspecialties all subspecialties asthma bronchitis chronic cough copd critical care cystic fibrosis emphysema lung cancer mechanical ventilation pneumonia practice management pulmonary vascular disease sarcoidosis sleep disorders smoking and tobacco tuberculosis healio news pulmonology pulmonary vascular disease by erin t. welsh, ma source hill n, et al.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_17_15_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_17_15.html"">Inhaled treprostinil improves QOL, other exploratory outcomes in patients with PAH"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,Treprostinil (1),"google_news | Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent Nasdaq:LQDA | ... 10,716,793 793 allegedly relating to utc's tyvaso, a nebulized <span style=""background-color: #FFFF00"">treprostinil</span> solution for the treatment of pulmonary arterial hypertension pah .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!24-07-2020_13_00_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_24-07-2020_13_00.html"">Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent Nasdaq:LQDA"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,Treprostinil (3),"google_news | Other news to note for July 23, 2020 | 2020-07-23 | BioWorld | ... the initiative upgrades an existing facility, complementing the vaccines manufacturing and innovation centre under construction in oxfordshire, u.k. united therapeutics corp., of silver spring, md., said the u.s. patent and trademark office issued a new patent on july 21, relating to pulmonary arterial hypertension drug tyvaso <span style=""background-color: #FFFF00"">treprostinil</span> inhalation solution, which expires may 14, 2027, and covering a method of administering <span style=""background-color: #FFFF00"">treprostinil</span> via inhalation, including claims covering the dosing regimen used to administer tyvaso.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!23-07-2020_22_45_RSS!!!Google_Search_CDK4-6_PR0_23-07-2020_22_45.html"">Other news to note for July 23, 2020 | 2020-07-23 | BioWorld"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"Treprostinil (6), treprostinil prodrug (2)","pr_newswire | Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update | ... <span style=""background-color: #FFFF00"">treprostinil</span> palmitil advancement insmed is advancing <span style=""background-color: #FFFF00"">treprostinil</span> palmitil, a dry powder, inhaled <span style=""background-color: #FFFF00"">treprostinil</span> prodrug formulation, for the potential treatment of pulmonary arterial hypertension and plans to initiate a phase 1 study by the end of 2020. ... the company plans to continue investing in the following key activities in 2020 i u.s. commercialization of arikayce; ii clinical trial activities, including a the development of a pro for ntm lung disease, the initiation of a study to validate the pro and, in parallel, a confirmatory clinical study of arikayce, b the advancement of brensocatib into a phase 3 program in patients with bronchiectasis, and c the advancement of <span style=""background-color: #FFFF00"">treprostinil</span> palmitil; and iii expansion in japan and europe to support pre commercial activities for arikayce in those regions and, pending approval of the marketing authorization application by the ec, launch activities in initial european countries.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_11_30_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR5_06-08-2020_11_30.html"">Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"Treprostinil (8), ralinepag (4), nitric oxide (1)","pr_newswire | United Therapeutics Corporation Reports Second Quarter 2020 Financial Results | ... we presented these and other highlights of the increase data at a recent virtual session of the american thoracic society entitled inhaled <span style=""background-color: #FFFF00"">treprostinil</span> in interstitial lung disease associated pulmonary hypertension the increase study. ... we submitted a 505 b 1 new drug application nda to the fda for our trevyent disposable <span style=""background-color: #FFFF00"">treprostinil</span> pump system in june 2019. ... <span style=""background-color: #FFFF00"">treprostinil</span> technosphere dry powder inhaler breeze. the breeze study nct03950739 seeks to evaluate 45 patients on a stable dose of tyvaso after switching to our new dry powder inhaler dpi form of <span style=""background-color: #FFFF00"">treprostinil</span>, which we licensed from mannkind.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_10_00_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR12_29-07-2020_10_00.html"">United Therapeutics Corporation Reports Second Quarter 2020 Financial Results"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"Treprostinil (6), treprostinil prodrug (2)","google_news | Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update - PharmiWeb.com | ... <span style=""background-color: #FFFF00"">treprostinil</span> palmitil advancement insmed is advancing <span style=""background-color: #FFFF00"">treprostinil</span> palmitil, a dry powder, inhaled <span style=""background-color: #FFFF00"">treprostinil</span> prodrug formulation, for the potential treatment of pulmonary arterial hypertension and plans to initiate a phase 1 study by the end of 2020. ... the company plans to continue investing in the following key activities in 2020 i u.s. commercialization of arikayce; ii clinical trial activities, including a the development of a pro for ntm lung disease, the initiation of a study to validate the pro and, in parallel, a confirmatory clinical study of arikayce, b the advancement of brensocatib into a phase 3 program in patients with bronchiectasis, and c the advancement of <span style=""background-color: #FFFF00"">treprostinil</span> palmitil; and iii expansion in japan and europe to support pre commercial activities for arikayce in those regions and, pending approval of the marketing authorization application by the ec, launch activities in initial european countries.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_12_00_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_12_00.html"">Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update - PharmiWeb.com"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"Treprostinil (6), treprostinil prodrug (2)","google_news | Form  8-K        INSMED Inc                For: Aug 06 | ... 2 <span style=""background-color: #FFFF00"">treprostinil</span> palmitil advancement insmed is advancing <span style=""background-color: #FFFF00"">treprostinil</span> palmitil, a dry powder, inhaled <span style=""background-color: #FFFF00"">treprostinil</span> prodrug formulation, for the potential treatment of pulmonary arterial hypertension and plans to initiate a phase 1 study by the end of 2020. ... the company plans to continue investing in the following key activities in 2020 i u.s. commercialization of arikayce; ii clinical trial activities, including a the development of a pro for ntm lung disease, the initiation of a study to validate the pro and, in parallel, a confirmatory clinical study of arikayce, b the advancement of brensocatib into a phase 3 program in patients with bronchiectasis, and c the advancement of <span style=""background-color: #FFFF00"">treprostinil</span> palmitil; and iii expansion in japan and europe to support pre commercial activities for arikayce in those regions and, pending approval of the marketing authorization application by the ec, launch activities in initial european countries.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_12_15_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_12_15.html"">Form  8-K        INSMED Inc                For: Aug 06"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"Treprostinil (2), treprostinil prodrug (1)","pr_newswire | Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options | ... insmed's earlier stage clinical pipeline includes brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non cystic fibrosis bronchiectasis and other inflammatory diseases, and <span style=""background-color: #FFFF00"">treprostinil</span> palmitil, an inhaled formulation of a <span style=""background-color: #FFFF00"">treprostinil</span> prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!24-07-2020_11_45_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR6_24-07-2020_11_45.html"">Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"sildenafil (6), sildenafil citrate (2)","google_news | Sildenafil Citrate Could Be Used To Treat Ocular Hypotension, Finds Study – Myhealthyclick.com | homehealthy living wednesday, july 22, 2020about uscontact us home<span style=""background-color: #FFFF00"">sildenafil citrate</span> could be used to treat ocular hypotension, finds studyin previous studies, sildenafil 50 mg and 100 mg was shown to produce a substantial increase of intraocular pressure in an animal model.by karen johnson july 22, 2020110share <span style=""background-color: #FFFF00"">sildenafil citrate</span>, sold under the brand name viagra for erectile dysfunction, has been found effective at treating ocular hypotension or shallow anterior chamber after surgery, according to a virtual presentation at the association for research in vision and ophthalmology conference.researcher dr. maria gomez chapo said, in previous studies, sildenafil 50 mg and 100 mg was shown to produce a substantial increase of intraocular pressure in an animal model.the purpose of the current study was to test the same drug in human volunteers with normal iop intraocular pressure in the city of corrientes, argentina.the study included 15 healthy participants, aged between 19 and 55, who were divided into two groups.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!22-07-2020_12_15_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_22-07-2020_12_15.html"">Sildenafil Citrate Could Be Used To Treat Ocular Hypotension, Finds Study  Myhealthyclick.com"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,"tadalafil (1), macitentan (1), selexipag (1)","google_news | PAH Caused by Undiagnosed Systemic Sclerosis in Case Study | ... following a meeting with specialists in lung disease, cardiology, and rheumatology, she was started on a triple combination of pah therapies which included the blood vessel dilators uptravi selexipag and opsumit macitentan , both marketed by actelion, along with adcirca <span style=""background-color: #FFFF00"">tadalafil</span>, marketed by united therapeutics .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_16_45_RSS!!!Google_Search_Crohn's%20Disease_PR1_29-07-2020_16_45.html"">PAH Caused by Undiagnosed Systemic Sclerosis in Case Study"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,tadalafil (1),"google_news | Number of Men Seeking Treatment for Low Libido and Peyronie's on the Rise - Gilmore Health News | ... our patients are also getting younger and younger, which could reflect a generational change in attitudes towards sexual problems.read also vigrx plus another male enhancement supplement tainted with <span style=""background-color: #FFFF00"">tadalafil</span> by counterfeiterspreliminary resultshowever, the researcher warns that these figures do not indicate any change in the prevalence of the disease.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!03-08-2020_16_30_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_03-08-2020_16_30.html"">Number of Men Seeking Treatment for Low Libido and Peyronies on the Rise - Gilmore Health News"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,imatinib (9),"google_news | Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy | aerovate therapeutics emerges from ra capital incubator with $72.6 million funding for potential disease modifying pulmonary arterial hypertension therapy globenewswire register sign in english franais contact us global distribution newswire services regulatory filings media partners aerovate therapeutics emerges from ra capital incubator with $72.6 million funding for potential disease modifying pulmonary arterial hypertension therapy av 101 is a proprietary inhaled version of <span style=""background-color: #FFFF00"">imatinib</span>, which has proven efficacy treating pah; aerovate was founded and seeded by ra capital management; series a is led by sofinnova investments; includes new investors atlas venture, cormorant asset management, surveyor capital and osage university partners share august 06, 2020 09 40 et source aerovate therapeutics boston, aug. 06, 2020 globe newswire aerovate therapeutics, inc., has closed on $72.6 million in series a funding to advance trials of av 101, an inhaled, dry powder aerosol version of <span style=""background-color: #FFFF00"">imatinib</span> to treat pulmonary arterial hypertension pah .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_13_45_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_13_45.html"">Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,imatinib (2),"google_news | Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium | ... our lead product candidate is an inhaled formulation of <span style=""background-color: #FFFF00"">imatinib</span> aer 901 delivered via a proprietary handheld nebulizer for the treatment of patients with pulmonary arterial hypertension pah , a progressive and currently incurable lung disease. ... in addition to pah, we plan to explore additional indications for aer 901 based on <span style=""background-color: #FFFF00"">imatinib</span>'s mechanism of action.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!23-07-2020_12_00_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_23-07-2020_12_00.html"">Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,sotatercept (6),"google_news | Fusion protein holds promise for treating pulmonary arterial hypertension: Study, Health News, ET HealthWorld | ... news sites retail news auto news telecom news energy news it news real estate news technology news cfo news it security news bfsi news government news brand equity hospitality news travel news hr news virtual conference news bu news sign in sign up follow us more x health newslatest health newsdiagnosticsfusion protein holds promise for treating pulmonary arterial hypertension studyby the time symptoms most notably, shortness of breath become severe enough for someone with pah to seek care and obtain a definitive diagnosis, the patient's chances of survival at five years are slightly better than 50 per cent on currently available treatments.ani july 26, 2020, 12 19 ist boston a new study has pointed out that symptoms of pulmonary arterial hypertension pah may begin slowly, and even before they appear, extensive damage has caused the obstruction of small arteries leading to increased blood pressure in the lungs.by the time symptoms most notably, shortness of breath become severe enough for someone with pah to seek care and obtain a definitive diagnosis, the patient's chances of survival at five years are slightly better than 50 per cent on currently available treatments.paul b yu, md, phd, a cardiovascular medicine specialist at brigham and women's hospital, has been studying pah for more than 15 years to better understand the fundamental process in which blood vessels in the lungs are lost to the disease.in a paper published in science translational medicine, members of yu's lab and co authors at brigham and women's hospital and acceleron pharma illuminate the underlying biological pathways that may lead to vessel destruction.their results provide a biological explanation for why proteins called activins and growth and differentiation factors gdfs might contribute to pulmonary vascular disease, and provide an explanation of how the activin gdf blocking drug <span style=""background-color: #FFFF00"">sotatercept</span>, currently in clinical trials, may help treat patients with pulmonary arterial hypertension.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!26-07-2020_06_45_RSS!!!Google_Search_Toll-like%20receptor%207_PR0_26-07-2020_06_45.html"">Fusion protein holds promise for treating pulmonary arterial hypertension: Study, Health News, ET HealthWorld"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,sotatercept (6),"google_news | Acceleron Reports Second Quarter 2020 Operating and Financial Results | Business Wire | ... our future development plan will support our long term vision for <span style=""background-color: #FFFF00"">sotatercept</span> to become a backbone therapy for patients with pah across all stages of disease. ... pulmonary <span style=""background-color: #FFFF00"">sotatercept</span> pulmonary arterial hypertension pah <span style=""background-color: #FFFF00"">sotatercept</span> is an investigational agent designed to be a selective ligand trap for members of the tgf beta superfamily to rebalance bmpr2 signaling, which is a key molecular driver of pah. in preclinical studies of pah, <span style=""background-color: #FFFF00"">sotatercept</span> rap 011 reversed pulmonary vessel muscularization and improved indicators of right heart failure.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_21_15_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_21_15.html"">Acceleron Reports Second Quarter 2020 Operating and Financial Results | Business Wire"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,sotatercept (1),"google_news | Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020 | Business Wire | ... in pulmonary, acceleron is developing <span style=""background-color: #FFFF00"">sotatercept</span> for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the phase 2 pulsar trial.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!27-07-2020_11_00_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_27-07-2020_11_00.html"">Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020 | Business Wire"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,sotatercept (1),"press_release | Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales | Acceleron Pharma Inc. | ... in pulmonary, acceleron is developing <span style=""background-color: #FFFF00"">sotatercept</span> for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the phase 2 pulsar trial.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020!!!Acceleron%20Pharma,%20Inc._PR2_06-08-2020.html"">Acceleron Announces Second Quarter 2020 REBLOZYL Net Sales | Acceleron Pharma Inc."
pulmonary_arterial_hypertension_NWSLTR_cooccurence,sotatercept (1),"press_release | Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales | Business Wire | ... in pulmonary, acceleron is developing <span style=""background-color: #FFFF00"">sotatercept</span> for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the phase 2 pulsar trial.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_11_00_RSS!!!BusinessWire_PR1_06-08-2020_11_00.html"">Acceleron Announces Second Quarter 2020 REBLOZYL Net Sales | Business Wire"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,sotatercept (1),"google_news | Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales - Odessa American: Business | ... in pulmonary, acceleron is developing <span style=""background-color: #FFFF00"">sotatercept</span> for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the phase 2 pulsar trial.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_11_30_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_11_30.html"">Acceleron Announces Second Quarter 2020 REBLOZYL Net Sales - Odessa American: Business"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,ralinepag (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">ralinepag</span> arena pharmaceuticals united therapeutics corporation 800031652  type: trial update date: 26 feb 2020  content: arena pharmaceuticals plans the phase iii trial advance capacity for pulmonary arterial hypertension in poland po in september 2020 nct04084678 media release updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_trial_update_290.html"">AdisInsight_2020-08-04_pharma&biotech"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,nitric oxide (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">nitric oxide</span> synthase therapy maxcyte northern therapeutics 800014363  type: trial update date: 29 jul 2020  content: northern therapeutics and ottawa hospital research institute re initiate the phase ii iii sapphire trial in pulmonary arterial hypertension in canada iv nct03001414 media release updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_trial_update_272.html"">AdisInsight_2020-08-04_pharma&biotech"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,R-107 (4),"Evaluate News | Evaluate_2020-08-04_Merger | headline: kalytera announces exclusive license agreement with salzman group for development and commercialization of <span style=""background-color: #FFFF00"">r 107</span> for treatment of coronavirus and covid 19 infection  source: press release company: kalytera therapeutics date: july 16, 2020  content: kalytera therapeutics, inc. tsx venture: kly and otc: kaltf the company or kalytera today announced that it has entered into a license agreement the license agreement with salzman group, inc. salzman group , under which salzman group has granted to kalytera an exclusive, worldwide license to develop and commercialize salzman group's proprietary drug, <span style=""background-color: #FFFF00"">r 107</span>, for the treatment of coronavirus and covid 19 infection.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/evaluate_email!!!2020-08-04!!!Evaluate_38_2020-08-04_HTML_Extract_7_Merger_&_Acquisition_News.html"">Evaluate_2020-08-04_Merger"
pulmonary_arterial_hypertension_NWSLTR_cooccurence,iloprost (1),"pr_newswire | Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer | ... mr. mahaffey also served as sr. vice president of sales and marketing at cotherix, inc. where he led commercialization of ventavis <span style=""background-color: #FFFF00"">iloprost</span> , an orphan drug to treat pulmonary arterial hypertension.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!27-07-2020_15_30_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR8_27-07-2020_15_30.html"">Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer"
uterine fibroids_ NWSLTR_cooccurence,linzagolix (2),"press_release | Home - ObsEva | ... read more our products our pipeline <span style=""background-color: #FFFF00"">linzagolix</span> obe2109 oral gnrh receptor antagonist milestones uterine fibroids maa nda 4q 20 1h 21 primrose 1 positive 24w primary endpoint results july2020 52w results expected 4q 20 primrose 2 positive 24w primary endpoint results dec2019 sustained efficacy and continued safety confirmed at 52w jul2020 76w post treatment follow up period results expected 4q 20 endometriosis initiated phase 3 in 2q 19 positive phase 2b results in 2018 19 commercial rights exclusive worldwide ex asia learn more obe022 oral and selective prostaglandin f2 alpha receptor antagonist milestones phase 2a results in 120 patients expected 2h 20pre clinical phase 1 complete commercial rights exclusive worldwide learn more nolasiban obe001 oral oxytocin receptor antagonist milestones resuming developmentyuyuan bioscience technology prc ind submission 2h 20 in china commercial rights exclusive worldwide ex china partnership with yuyuan bioscience technology prc learn more latest press release obseva announces second quarter 2020 financial results and business update august 6, 2020 primary endpoint successfully met in phase 3 primrose 1 trial of <span style=""background-color: #FFFF00"">linzagolix</span> for the treatment of heavy menstrual bleeding due learn more obseva in the media learn more other obseva press releases learn more work with us are you ready to join an innovative biopharmaceutical company that's advancing women's reproductive health and pregnancy therapeutics currently we have no open vacancies but you can always join our talent community below.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020!!!ObsEva%20SA_PR1_06-08-2020.html"">Home - ObsEva"
uterine fibroids_ NWSLTR_cooccurence,ulipristal (8),"IPD | ipd | ... ellaone <span style=""background-color: #FFFF00"">ulipristal</span> acetate october 1 epo appeal in may 2009, the ema approved <span style=""background-color: #FFFF00"">ulipristal</span> under the name ellaone for postcoital contraception. in february 2012, the ema approved <span style=""background-color: #FFFF00"">ulipristal</span> for uterine fibroids leiomyomata under the name esmya. ... the 108 patent covers methods of using 30 mg <span style=""background-color: #FFFF00"">ulipristal</span> acetate administered within 120 hours for contraception after intercourse.in november 2018, the epos opposition division revoked the 108 patent in opposition proceedings initiated by egis, helm, mylan, sandozs hexal, stada, and teva.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/IPD!!!2020-07-28!!!ipd_74392_2020-07-28.html"">ipd"
uterine fibroids_ NWSLTR_cooccurence,ulipristal (8),"IPD | ipd | ... ellaone <span style=""background-color: #FFFF00"">ulipristal</span> acetate october 1 epo appeal in may 2009, the ema approved <span style=""background-color: #FFFF00"">ulipristal</span> under the name ellaone for postcoital contraception. in february 2012, the ema approved <span style=""background-color: #FFFF00"">ulipristal</span> for uterine fibroids leiomyomata under the name esmya. ... the 108 patent covers methods of using 30 mg <span style=""background-color: #FFFF00"">ulipristal</span> acetate administered within 120 hours for contraception after intercourse.in november 2018, the epos opposition division revoked the 108 patent in opposition proceedings initiated by egis, helm, mylan, sandozs hexal, stada, and teva.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/IPD!!!2020-08-04!!!ipd_75134_2020-08-04.html"">ipd"
uterine fibroids_ NWSLTR_cooccurence,relugolix (17),"press_release | ene20200806.pdf | ene20200806.pdf myovant sciences announces further financing support from sumitomo dainippon pharma and commercial collaboration with sunovion pharmaceuticals august 5, 2020 usd 200 million low interest, five year term loan commitment from sumitomo dainippon pharma to further support planned commercialization of <span style=""background-color: #FFFF00"">relugolix</span> across multiple indications agreement with sunovion pharmaceuticals provides access to well established commercial infrastructure currently utilized across multiple successful products basel, switzerland, aug. 05, 2020 globe newswire myovant sciences nyse myov , a healthcare company focused on redefining care for women and for men, today announced a usd 200 million low interest, five year term loan commitment from sumitomo dainippon pharma co., ltd. tse 4506 , bringing its total financing support for myovant to usd 600 million, further bolstering myovant's cash and committed funding and increasing the company's financing flexibility as it prepares for multiple potential product launches to treat advanced prostate cancer, uterine fibroids, and endometriosis.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!pdf!!!06-08-2020!!!Sumitomo%20Dainippon%20Pharma%20Co.,%20Ltd._PR1_06-08-2020.pdf"">ene20200806.pdf"
uterine fibroids_ NWSLTR_cooccurence,relugolix (4),"google_news | Financings for Aug. 5, 2020 | 2020-08-05 | BioWorld | ... additionally, myovant reported it had entered a three year commercial collaboration agreement with sunovion pharmaceuticals inc., an indirect, wholly owned subsidiary of sumitomo dainippon pharma, for services to support the planned commercialization of investigational drug candidate <span style=""background-color: #FFFF00"">relugolix</span>. it will become a nonexclusive distributor of <span style=""background-color: #FFFF00"">relugolix</span> for prostate cancer and the exclusive distributor of <span style=""background-color: #FFFF00"">relugolix</span> combination tablet for uterine fibroids and endometriosis in the u.s. <span style=""background-color: #FFFF00"">relugolix</span> 120 mg is under fda priority review for the treatment of men with advanced prostate cancer, with a target action date of dec. 20, 2020.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!05-08-2020_23_00_RSS!!!Google_Search_Immunic_PR0_05-08-2020_23_00.html"">Financings for Aug. 5, 2020 | 2020-08-05 | BioWorld"
cystic fibrosis_ NWSLTR_cooccurence,"gene therapy (18), Airway (4), ivacaftor (3)","press_release | Gene therapy could offer an inclusive cure for cystic fibrosis | <span style=""background-color: #FFFF00"">gene therapy</span> could offer an inclusive cure for cystic fibrosis skip to main content advertisement thank you for visiting nature.com. ... natureoutlookarticle a nature research journal outlook 29 july 2020 <span style=""background-color: #FFFF00"">gene therapy</span> could offer an inclusive cure for cystic fibrosis after three decades of false starts, <span style=""background-color: #FFFF00"">gene therapy</span> against the disease is in new clinical trials and there is even hope of a cure. ... for patients like henry, genetic therapies are the most promising hope for a healthy life.scientists have been trying for 30 years to wield <span style=""background-color: #FFFF00"">gene therapy</span> against cystic fibrosis.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_13_45_RSS!!!Nature%20Feed_PR1_29-07-2020_13_45.html"">Gene therapy could offer an inclusive cure for cystic fibrosis"
cystic fibrosis_ NWSLTR_cooccurence,"ivacaftor (6), gene therapy (4), Airway (1)","press_release | In utero intervention to stem the damage of cystic fibrosis | ... and <span style=""background-color: #FFFF00"">gene therapy</span> could even be used to fix the faulty cftr gene before birth. ... more than 20 years ago, a team led by neonatologist janet larson at the ochsner medical foundation in new orleans, louisiana, described the first application of in utero <span style=""background-color: #FFFF00"">gene therapy</span> in mouse models of the disease1. ... then came the death, in 1999, of an 18 year old volunteer in an experimental <span style=""background-color: #FFFF00"">gene therapy</span> study unrelated to cystic fibrosis . this set the entire field of <span style=""background-color: #FFFF00"">gene therapy</span> back many years.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_13_45_RSS!!!Nature%20Feed_PR7_29-07-2020_13_45.html"">In utero intervention to stem the damage of cystic fibrosis"
cystic fibrosis_ NWSLTR_cooccurence,gene therapy (3),"press_release | CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments | ... that meant patients would have to be treated with technologies that can target the gene <span style=""background-color: #FFFF00"">gene therapy</span>, gene editing, and rna drugs, among others. ... one of the challenges right now is that there are easier targets for <span style=""background-color: #FFFF00"">gene therapy</span> than cf, boyle said. it's difficult to get <span style=""background-color: #FFFF00"">gene therapy</span> into the lungs, where the immune response is unique and cells turn over at a higher rate than in other parts of the body.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!05-08-2020!!!EndPoints_PR3_05-08-2020.html"">CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments"
cystic fibrosis_ NWSLTR_cooccurence,"ivacaftor (5), CFTR modulator (3), gene therapy (1)","press_release | Cystic fibrosis drugs target the malformed proteins at the root of the disease | ... <span style=""background-color: #FFFF00"">gene therapy</span> promises a way to cure the disease by addressing the root cause.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_13_45_RSS!!!Nature%20Feed_PR9_29-07-2020_13_45.html"">Cystic fibrosis drugs target the malformed proteins at the root of the disease"
cystic fibrosis_ NWSLTR_cooccurence,gene therapy (1),"google_news | GlycoNet invests $3.9 million to address research gaps in Canadian healthcare | EurekAlert! Science News | ... the identified targets will also provide therapeutic insight for diseases in humans such as salmonellosis, crohn's disease, colitis, and colon cancer.lead investigator wesley zandberg university of british columbia okanagan co investigators douglas inglis agriculture and agri food canada , wade abbott agriculture and agri food canada , alisdair boraston university of victoria , richard uwiera university of alberta , steven smith queen's university , chantelle capicciotti queen's university innovate therapies for neurological lysosomal storage disordersthe team will test novel therapeutic approaches including gene stem cell correction and small molecules to cure or ameliorate sanfilippo disease, a genetic disease that causes mental retardation, progressive dementia in children leading to early death in their twenties.lead investigator alexey pshezhetsky chu ste justine co investigators christopher cairo university of alberta , gregory lodygensky chu ste justine , christian beausejour chu ste justine identification of targets of glucocerebrosidase gcase activators and optimization of positron emission tomography imaging agentsthrough studying a carbohydrate processing enzyme, the research team will develop an imaging tool that will shed light on the progression of parkinson's disease.lead investigator david vocadlo simon fraser university co investigators vesna sossi university of british columbia , paul schaffer triumf , edward fon mcgill university , thomas durcan mcgill phase 1 2a clinical trial for treatment of tay sachs and sandhoff diseases using aav9 hex <span style=""background-color: #FFFF00"">gene therapy</span>researchers will carry out the first canadian <span style=""background-color: #FFFF00"">gene therapy</span> trial that removes the excess buildup of glycan modified fat gm2 gangliosides in the brain as a treatment for genetic disorders tay sachs and sandhoff diseases.lead investigator jagdeep walia queen's university co investigators inka brockhausen queen's university , denis lehotay queen's university modulatory and therapeutic roles of gangliosides in neurodegeneration and neuroinflammationthe team will study the mechanisms by which gangliosides, a type of glycolipids, protect against neurodegeneration, and determine an optimal method to deliver a potential therapeutic to treat neurodegenerative diseases.lead investigator simonetta sipione university of alberta co investigators john klassen university of alberta , matthew macauley university of alberta regulation of inflammatory response to bacterial infections by human neuraminidase enzymesresearchers aim to gain a better understanding of the role of neuraminidase enzymes in the immune system during infection.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!23-07-2020_14_30_RSS!!!Google_Search_Crohn's%20Disease_PR0_23-07-2020_14_30.html"">GlycoNet invests $3.9 million to address research gaps in Canadian healthcare | EurekAlert! Science News"
cystic fibrosis_ NWSLTR_cooccurence,murepavadin (1),"press_release | Media release detail page – Polyphor | ... the company's lead ompta program is an inhaled formulation of <span style=""background-color: #FFFF00"">murepavadin</span> for the treatment of pseudomonas aeruginosa infections in patients with cystic fibrosis.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!03-08-2020!!!Polyphor%20Ltd_PR1_03-08-2020.html"">Media release detail page  Polyphor"
cystic fibrosis_ NWSLTR_cooccurence,"ivacaftor (2), Airway (2), CFTR modulator (1)","press_release | Research round-up: Cystic fibrosis | ... fifteen patients had a well characterized mutation s1251n , which is responsive to the <span style=""background-color: #FFFF00"">cftr modulator</span> ivacaftor.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_13_45_RSS!!!Nature%20Feed_PR8_29-07-2020_13_45.html"">Research round-up: Cystic fibrosis"
cystic fibrosis_ NWSLTR_cooccurence,ciprofloxacin (1),"press_release | Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually | Business Wire | ... apulmiq is an inhaled <span style=""background-color: #FFFF00"">ciprofloxacin</span> in phase 3 development for non cystic fibrosis bronchiectasis ncfb .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!05-08-2020_12_00_RSS!!!BusinessWire_PR0_05-08-2020_12_00.html"">Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually | Business Wire"
cystic fibrosis_ NWSLTR_cooccurence,ciprofloxacin (1),"press_release | Savara to Report Second Quarter 2020 Financial Results and Provide Business Update  | Business Wire | ... apulmiq is an inhaled <span style=""background-color: #FFFF00"">ciprofloxacin</span> in phase 3 development for non cystic fibrosis bronchiectasis ncfb .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!30-07-2020_12_00_RSS!!!BusinessWire_PR1_30-07-2020_12_00.html"">Savara to Report Second Quarter 2020 Financial Results and Provide Business Update  | Business Wire"
cystic fibrosis_ NWSLTR_cooccurence,ciprofloxacin (1),"google_news | Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually | Business | valdostadailytimes.com | ... apulmiq is an inhaled <span style=""background-color: #FFFF00"">ciprofloxacin</span> in phase 3 development for non cystic fibrosis bronchiectasis ncfb .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!05-08-2020_12_30_RSS!!!Google_Search_Granulocyte-macrophage%20colony-stimulating%20factor_PR0_05-08-2020_12_30.html"">Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually | Business | valdostadailytimes.com"
cystic fibrosis_ NWSLTR_cooccurence,ciprofloxacin (1),"press_release | Savara Reports Second Quarter 2020 Financial Results and Provides Business Update | Business Wire | ... apulmiq is an inhaled <span style=""background-color: #FFFF00"">ciprofloxacin</span> in phase 3 development for non cystic fibrosis bronchiectasis ncfb .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_21_15_RSS!!!BusinessWire_PR32_06-08-2020_21_15.html"">Savara Reports Second Quarter 2020 Financial Results and Provides Business Update | Business Wire"
cystic fibrosis_ NWSLTR_cooccurence,ciprofloxacin (1),"google_news | Savara Reports Second Quarter 2020 Financial Results and Provides Business Update | Business | valdostadailytimes.com | ... apulmiq is an inhaled <span style=""background-color: #FFFF00"">ciprofloxacin</span> in phase 3 development for non cystic fibrosis bronchiectasis ncfb .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_21_15_RSS!!!Google_Search_Granulocyte-macrophage%20colony-stimulating%20factor_PR0_06-08-2020_21_15.html"">Savara Reports Second Quarter 2020 Financial Results and Provides Business Update | Business | valdostadailytimes.com"
cystic fibrosis_ NWSLTR_cooccurence,"tobramycin (80), Fosfomycin (10), ciprofloxacin (2), meropenem (1)","press_release | Rapid and robust evolution of collateral sensitivity in Pseudomonas aeruginosa antibiotic-resistant mutants | Science Advances | ... tob, tobramycin; tgc, tigecycline; caz, ceftazidime; cip, <span style=""background-color: #FFFF00"">ciprofloxacin</span>; ipm, imipenem.view this table:view popupview inlineevolutionary robustness of first steps of p. aeruginosa ceftazidime resistance evolution and collateral sensitivity to tobramycinto determine whether chromosomal deletions containing mexxy would be early selected during p. aeruginosa evolution in presence of ceftazidime in the set of mutants mentioned above, as it was the case in the wild type strain pa14 25 , four biological replicates of each single nfxb177, parr87, mexz43, orfn50, and nuod184 and multiple mutants mdr6 and mdr12 , and the wild type pa14 strain, were subjected to ale in presence or absence of ceftazidime a total of 64 populations for 3 days.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!05-08-2020_18_15_RSS!!!Intron%20Biotechnology_PR5_05-08-2020_18_15.html"">Rapid and robust evolution of collateral sensitivity in Pseudomonas aeruginosa antibiotic-resistant mutants | Science Advances"
cystic fibrosis_ NWSLTR_cooccurence,ETD-002 (1),"Adis Insight | AdisInsight_2020-08-04_non-industry | headline: <span style=""background-color: #FFFF00"">etd 002</span> 800056303  type: phase change i date: 30 jul 2020  content: enterprise therapeutics plans clinical trial for cystic fibrosis in late 2019 enterprise therapeutics pipeline, october 2019 media release updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_non-industry_drugs_phase_change__i_24.html"">AdisInsight_2020-08-04_non-industry"
cystic fibrosis_ NWSLTR_cooccurence,ETD-002 (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">etd 002</span> 800056303  type: phase change i date: 30 jul 2020  content: enterprise therapeutics plans clinical trial for cystic fibrosis in late 2019 enterprise therapeutics pipeline, october 2019 media release updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_phase_change__i_167.html"">AdisInsight_2020-08-04_pharma&biotech"
cystic fibrosis_ NWSLTR_cooccurence,"ivacaftor (6), tezacaftor + ivacaftor (3), elexacaftor + tezacaftor + ivacaftor (2)","Evaluate News | Evaluate_2020-08-04_Late | headline: positive phase 3 study results for trikafta elexacaftor tezacaftor <span style=""background-color: #FFFF00"">ivacaftor</span> and <span style=""background-color: #FFFF00"">ivacaftor</span> in people ages 12 and older with cystic fibrosis who have one copy of the f508del mutation and one gating or residual function mutation  source: news company: european medicines agency, vertex pharmaceuticals date: july 20, 2020  content: phase 3 study met primary endpoint and all secondary endpoints study is a u.s. post marketing commitment and will be submitted to fda data also will be submitted to the european medicines agency to support indication expansion of the eu label following triple combination approval vertex pharmaceuticals incorporated nasdaq: vrtx today announced results of a global phase 3 study of trikafta elexacaftor tezacaftor <span style=""background-color: #FFFF00"">ivacaftor</span> and <span style=""background-color: #FFFF00"">ivacaftor</span> in people with cystic fibrosis cf ages 12 years and older who have one copy of the f508del mutation and one gating mutation f g or one copy of the f508del mutation and one residual function mutation f rf .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/evaluate_email!!!2020-08-04!!!Evaluate_36_2020-08-04_HTML_Extract_0_Late_Stage_R&D_News.html"">Evaluate_2020-08-04_Late"
cystic fibrosis_ NWSLTR_cooccurence,ivacaftor (2),"Adis Insight | AdisInsight_2020-08-04_non-industry | headline: <span style=""background-color: #FFFF00"">ivacaftor</span> vertex pharmaceuticals 800024369  type: regulatory status date: 03 aug 2020  content: the chmp of ema recommends approval of <span style=""background-color: #FFFF00"">ivacaftor</span> for treatment of cystic fibrosis monotherapy, combination therapy, in adolescents, in children, in adults with an r117h cftr mutation internet updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_non-industry_drugs_regulatory_status_4.html"">AdisInsight_2020-08-04_non-industry"
cystic fibrosis_ NWSLTR_cooccurence,ivacaftor (2),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">ivacaftor</span> vertex pharmaceuticals 800024369  type: regulatory status date: 03 aug 2020  content: the chmp of ema recommends approval of <span style=""background-color: #FFFF00"">ivacaftor</span> for treatment of cystic fibrosis monotherapy, combination therapy, in adolescents, in children, in adults with an r117h cftr mutation internet updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_regulatory_status_97.html"">AdisInsight_2020-08-04_pharma&biotech"
cystic fibrosis_ NWSLTR_cooccurence,ivacaftor (1),"Adis Insight | AdisInsight_2020-08-04_non-industry | headline: internet  type: regulatory status date: 03 aug 2020  content: the chmp of ema recommends approval of <span style=""background-color: #FFFF00"">ivacaftor</span> for treatment of cystic fibrosis monotherapy, combination therapy, in adolescents, in children, in adults with an r117h cftr mutation internet updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_non-industry_drugs_regulatory_status_5.html"">AdisInsight_2020-08-04_non-industry"
cystic fibrosis_ NWSLTR_cooccurence,ivacaftor (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: internet  type: regulatory status date: 03 aug 2020  content: the chmp of ema recommends approval of <span style=""background-color: #FFFF00"">ivacaftor</span> for treatment of cystic fibrosis monotherapy, combination therapy, in adolescents, in children, in adults with an r117h cftr mutation internet updated 03 aug 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_135_2020-08-04_pharma&biotech_drugs_regulatory_status_98.html"">AdisInsight_2020-08-04_pharma&biotech"
cystic fibrosis_ NWSLTR_cooccurence,ivacaftor (2),"press_release | How much protein function needs to be restored in cystic fibrosis? | ... the confluence of all these studies is something of a road map for what cftr level each organ needs in order to be normal, says rowe.a drug called <span style=""background-color: #FFFF00"">ivacaftor</span> was shown to boost cftr function during clinical trials in 2008 by opening the faulty chloride channels. <span style=""background-color: #FFFF00"">ivacaftor</span> gave 50% more function in the lab, but 30% in real life, says rowe.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_13_45_RSS!!!Nature%20Feed_PR2_29-07-2020_13_45.html"">How much protein function needs to be restored in cystic fibrosis?"
cystic fibrosis_ NWSLTR_cooccurence,"Airway (4), ivacaftor (2)","press_release | The gender gap in cystic fibrosis | ... some anticipated it might be a difficult riddle to solve, with an answer spanning multiple disciplines.the gender gap mysterya decade and a half after that us analysis, a medication called <span style=""background-color: #FFFF00"">ivacaftor</span> marketed as kalydeco by vertex pharmaceuticals of boston, massachusetts became available. ... marketed as trikafta by vertex pharmaceuticals, the treatment is a twice daily combination of three cftr modulators elexacaftor, <span style=""background-color: #FFFF00"">ivacaftor</span> and tezacaftor.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!29-07-2020_13_45_RSS!!!Nature%20Feed_PR6_29-07-2020_13_45.html"">The gender gap in cystic fibrosis"
cystic fibrosis_ NWSLTR_cooccurence,"ivacaftor (2), elexacaftor + tezacaftor + ivacaftor (1), tezacaftor + ivacaftor (1)","google_news | Biopharma sector’s Q2 earning updates buffeted and braced by pandemic | 2020-07-31 | BioWorld | ... vertex, of boston, also turned in a strong beat on thursday, with second quarter product revenues hitting $1.52 billion, driven in large part by uptake of the company's new cystic fibrosis cf drug, trikafta elexacaftor tezacaftor <span style=""background-color: #FFFF00"">ivacaftor</span> and <span style=""background-color: #FFFF00"">ivacaftor</span> .",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!31-07-2020_22_15_RSS!!!Google_Search_Peanut%20Allergy_PR0_31-07-2020_22_15.html"">Biopharma sectors Q2 earning updates buffeted and braced by pandemic | 2020-07-31 | BioWorld"
cystic fibrosis_ NWSLTR_cooccurence,"mannitol (1), Airway (1)","pr_newswire | Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update | ... avoid concomitant use of arikayce with ethacrynic acid, furosemide, urea, or intravenous <span style=""background-color: #FFFF00"">mannitol</span>.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_11_30_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR5_06-08-2020_11_30.html"">Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update"
cystic fibrosis_ NWSLTR_cooccurence,"mannitol (1), Airway (1)","pr_newswire | Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options | ... avoid concomitant use of arikayce with ethacrynic acid, furosemide, urea, or intravenous <span style=""background-color: #FFFF00"">mannitol</span>.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!24-07-2020_11_45_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR6_24-07-2020_11_45.html"">Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options"
cystic fibrosis_ NWSLTR_cooccurence,"mannitol (1), Airway (1)","google_news | Form  8-K        INSMED Inc                For: Aug 06 | ... avoid concomitant use of arikayce with ethacrynic acid, furosemide, urea, or intravenous <span style=""background-color: #FFFF00"">mannitol</span>.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_12_15_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_12_15.html"">Form  8-K        INSMED Inc                For: Aug 06"
cystic fibrosis_ NWSLTR_cooccurence,"mannitol (1), Airway (1)","google_news | Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update - PharmiWeb.com | ... avoid concomitant use of arikayce with ethacrynic acid, furosemide, urea, or intravenous <span style=""background-color: #FFFF00"">mannitol</span>.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_12_00_RSS!!!Google_Search_Pulmonary%20Arterial%20Hypertension_PR0_06-08-2020_12_00.html"">Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update - PharmiWeb.com"
cystic fibrosis_ NWSLTR_cooccurence,nitric oxide (9),"press_release | News Detail  |  Mallinckrodt Pharmaceuticals | ... i agree newsroom in this section news release mallinckrodt initiates proof of concept study of <span style=""background-color: #FFFF00"">nitric oxide</span> gas in ex vivo system of human lung transplants study begins evaluation on first set of lungs, will assess organs using proprietary grading system staines upon thames, united kingdom, aug. 1, 2018 prnewswire mallinckrodt plc nyse mnk , a leading global specialty pharmaceutical company, today announced it has initiated a company sponsored, experimental, proof of concept study of <span style=""background-color: #FFFF00"">nitric oxide</span> gas with ex vivo lung perfusion compared to lung perfusion alone in human lung transplants.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020!!!Mallinckrodt%20plc_PR54_06-08-2020.html"">News Detail  |  Mallinckrodt Pharmaceuticals"
cystic fibrosis_ NWSLTR_cooccurence,ARO-ENaC (3),"Evaluate News | Evaluate_2020-08-04_Late | headline: arrowhead pharmaceuticals hosts key opinion leader webinar on <span style=""background-color: #FFFF00"">aro enac</span> for treatment of cystic fibrosis  source: news company: arrowhead pharmaceuticals date: july 28, 2020  content: arrowhead pharmaceuticals inc. nasdaq: arwr is hosting a key opinion leader webinar today at 12:00 pm edt on <span style=""background-color: #FFFF00"">aro enac</span>, the company's investigational rna interference rnai therapeutic being developed as a treatment for patients with cystic fibrosis cf . ... arrowhead management is providing a review of the <span style=""background-color: #FFFF00"">aro enac</span> program, which utilizes arrowhead's proprietary targeted rnai molecule trim platform and is the company's first inhaled rnai candidate to target pulmonary epithelium.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/evaluate_email!!!2020-08-04!!!Evaluate_112_2020-08-04_HTML_Extract_28_Late_Stage_R&D_News.html"">Evaluate_2020-08-04_Late"
cystic fibrosis_ NWSLTR_cooccurence,ARO-ENaC (1),"Adis Insight | AdisInsight_2020-08-04_pharma&biotech | headline: <span style=""background-color: #FFFF00"">aro enac</span> 800056219  type: trial update date: 28 jul 2020  content: arrowhead pharmaceuticals plans the phase i ii aroenac1001 trial for cystic fibrosis in volunteers and patients august 2020 media release updated 31 jul 2020",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/AdisInsight!!!2020-08-04!!!_AdisInsight_128_2020-08-04_pharma&biotech_drugs_trial_update_285.html"">AdisInsight_2020-08-04_pharma&biotech"
cystic fibrosis_ NWSLTR_cooccurence,ARO-ENaC (1),"press_release | Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results | Arrowhead Pharmaceuticals Inc. | ... selected recent events hosted a key opinion leader webinar on <span style=""background-color: #FFFF00"">aro enac</span>, the company's investigational rnai therapeutic being developed as a treatment for patients with cystic fibrosis completed dosing in healthy volunteer cohorts in arohsd1001, a phase 1 2 clinical study of aro hsd, the company's investigational rnai therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis completed dosing of the first sequential cohort and collected the first 6 month repeat biopsy in the aroaat2002 study, a pilot open label, multi dose, phase 2 study to assess changes in a novel histological activity scale in response to aro aat over time in patients with alpha 1 antitrypsin deficiency associated liver disease completed planned enrollment and dosing of 93 subjects in aroang1001, a phase 1 2 clinical study of aro ang3, the company's investigational rnai therapeutic being developed for the treatment of mixed dyslipidemia selected fiscal 2020 third quarter financial results arrowhead pharmaceuticals, inc. consolidated condensed financial information unaudited three months ended june 30, nine months ended june 30, operating summary 2020 2019 2020 2019 revenue $ 27,375,778 $ 42,696,636 $ 80,359,211 $ 125,502,807 operating expenses research and development 32,573,134 19,291,710 85,390,086 57,662,381 general and administrative expenses 10,748,506 4,809,177 38,008,836 16,287,841 total operating expenses 43,321,640 24,100,887 123,398,922 73,950,222 operating income loss 15,945,862 18,595,749 43,039,711 51,552,585 other income expense , provision for income taxes 2,334,649 1,739,959 6,919,200 4,717,359 net income loss $ 13,611,213 $ 20,335,708 $ 36,120,511 $ 56,269,944 net income loss per share diluted $ 0.13 $ 0.21 $ 0.36 $ 0.58 weighted average shares outstanding diluted 101,843,436 98,884,744 100,184,216 97,814,019 financial position summary june 30, september 30, 2020 2019 cash and cash equivalents $ 219,322,617 $ 221,804,128 short term investments 67,709,263 36,899,894 long term investments 177,529,881 44,175,993 total cash resources cash and investments 464,561,761 302,880,015 other assets 91,166,311 46,965,422 total assets 555,728,072 349,845,437 total current deferred revenue 26,274,362 77,769,629 total long term deferred revenue 5,035,142 other liabilities 36,868,505 23,004,414 total liabilities 63,142,867 105,809,185 total stockholders' equity 492,585,205 244,036,252 total liabilities and stockholders' equity $ 555,728,072 $ 349,845,437 shares outstanding 102,250,872 95,506,271 about arrowhead pharmaceuticals arrowhead pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020!!!Arrowhead%20Pharmaceuticals,%20Inc._PR1_06-08-2020.html"">Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results | Arrowhead Pharmaceuticals Inc."
cystic fibrosis_ NWSLTR_cooccurence,ARO-ENaC (1),"press_release | Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results | ... selected recent events earned a $20 million milestone payment from amgen following the administration of the first dose of amg 890, formerly referred to as aro lpa, in a phase 2 clinical study hosted a key opinion leader webinar on <span style=""background-color: #FFFF00"">aro enac</span>, the company's investigational rnai therapeutic being developed as a treatment for patients with cystic fibrosis completed dosing in healthy volunteer cohorts in arohsd1001, a phase 1 2 clinical study of aro hsd, the company's investigational rnai therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis completed dosing of the first sequential cohort and collected the first 6 month repeat biopsy in the aroaat2002 study, a pilot open label, multi dose, phase 2 study to assess changes in a novel histological activity scale in response to aro aat over time in patients with alpha 1 antitrypsin deficiency associated liver disease completed planned enrollment and dosing of 93 subjects in aroang1001, a phase 1 2 clinical study of aro ang3, the company's investigational rnai therapeutic being developed for the treatment of mixed dyslipidemia completed planned enrollment and dosing of 80 subjects in aroapoc31001, a phase 1 2 clinical study of aro apoc3, the company's investigational rnai therapeutic being developed for the treatment of hypertriglyceridemia, and expanded the study to include up to 112 subjects selected fiscal 2020 third quarter financial results arrowhead pharmaceuticals, inc. consolidated condensed financial information unaudited three months ended june 30, nine months ended june 30, operating summary 2020 2019 2020 2019 revenue $ 27,375,778 $ 42,696,636 $ 80,359,211 $ 125,502,807 operating expenses research and development 32,573,134 19,291,710 85,390,086 57,662,381 https cts.businesswire.com ct ct id=smartlink url=http%3a%2f%2fir.arrowheadpharma.com%2fevents.cfm esheet=52261877 newsitemid=20200805005880 lan=en us anchor=http%3a%2f%2fir.arrowheadpharma.com%2fevents.cfm index=1 md5=62f34bec0de02ef5d9be307326f48481 general and administrative expenses 10,748,506 4,809,177 38,008,836 16,287,841 total operating expenses 43,321,640 24,100,887 123,398,922 73,950,222 operating income loss 15,945,862 18,595,749 43,039,711 51,552,585 other income expense , provision for income taxes 2,334,649 1,739,959 6,919,200 4,717,359 net income loss $ 13,611,213 $ 20,335,708 $ 36,120,511 $ 56,269,944 net income loss per share diluted $ 0.13 $ 0.21 $ 0.36 $ 0.58 weighted average shares outstanding diluted 101,843,436 98,884,744 100,184,216 97,814,019 financial position summary june 30, september 30, 2020 2019 cash and cash equivalents $ 219,322,617 $ 221,804,128 short term investments 67,709,263 36,899,894 long term investments 177,529,881 44,175,993 total cash resources cash and investments 464,561,761 302,880,015 other assets 91,166,311 46,965,422 total assets 555,728,072 349,845,437 total current deferred revenue 26,274,362 77,769,629 total long term deferred revenue 5,035,142 other liabilities 36,868,505 23,004,414 total liabilities 63,142,867 105,809,185 total stockholders' equity 492,585,205 244,036,252 total liabilities and stockholders' equity $ 555,728,072 $ 349,845,437 shares outstanding 102,250,872 95,506,271 about arrowhead pharmaceuticals arrowhead pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!pdf!!!06-08-2020!!!Arrowhead%20Pharmaceuticals,%20Inc._PR2_06-08-2020.pdf"">Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results"
cystic fibrosis_ NWSLTR_cooccurence,Airway (1),"press_release | Use of IL-6-elafin genetically modified regulatory macrophages as an immunotherapeutic against acute bacterial infection in the lung | bioRxiv | ... conclusion here we introduce an immunotherapy approach employing gene modified syngeneic macrophages to target bacterial <span style=""background-color: #FFFF00"">airway</span> infections.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!23-07-2020_21_15_RSS!!!BioRXiv_PR1_23-07-2020_21_15.html"">Use of IL-6-elafin genetically modified regulatory macrophages as an immunotherapeutic against acute bacterial infection in the lung | bioRxiv"
cystic fibrosis_ NWSLTR_cooccurence,Airway (1),"press_release | Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps | Novartis | ... euforea the european forum for research and education in allergy and <span style=""background-color: #FFFF00"">airway</span> diseases about xolair omalizumab xolair is the only approved anti immunoglobulin e ige antibody treatment specifically designed to target and block ige.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020!!!Selexys%20Pharmaceuticals%20Corporation_PR5_06-08-2020.html"">Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps | Novartis"
cystic fibrosis_ NWSLTR_cooccurence,alidornase alfa (4),"pr_newswire | Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases | ... general inquiries request a demo editorial bureaus partnerships media inquiries worldwide offices protalix biotherapeutics enters into non binding term sheet with sarcomed usa to develop <span style=""background-color: #FFFF00"">alidornase alfa</span> for the treatment of pulmonary sarcoidosis and related diseases english news provided by jul 23, 2020, 14 29 et share this article carmiel, israel, july 23, 2020 prnewswire protalix biotherapeutics, inc. nyse american plx tase plx , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary procellex plant cell based protein expression system, today announced that it has entered into a non binding term sheet with sarcomed usa inc.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!23-07-2020_18_30_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR9_23-07-2020_18_30.html"">Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases"
cystic fibrosis_ NWSLTR_cooccurence,alidornase alfa (1),"pr_newswire | Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020 | ... protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates pegunigalsidase alfa, a modified version of the recombinant human galactosidasea protein for the proposed treatment of fabry disease; oprx106, an orally delivered anti inflammatory treatment; <span style=""background-color: #FFFF00"">alidornase alfa</span> for the treatment of cystic fibrosis; and prx 115, a plant cell expressed recombinant pegylated uricase for the treatment of gout.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!06-08-2020_17_00_RSS!!!PRNWs-medical_and_pharmaceutical_PR5_06-08-2020_17_00.html"">Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020"
cystic fibrosis_ NWSLTR_cooccurence,alidornase alfa (1),"pr_newswire | Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020 | ... protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates pegunigalsidase alfa, a modified version of the recombinant human galactosidasea protein for the proposed treatment of fabry disease; oprx 106, an orally delivered anti inflammatory treatment; <span style=""background-color: #FFFF00"">alidornase alfa</span> for the treatment of cystic fibrosis; and others.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!03-08-2020_13_15_RSS!!!PRNWs-Clinical_Trials&Medical_Discoveries_PR16_03-08-2020_13_15.html"">Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020"
cystic fibrosis_ NWSLTR_cooccurence,ensifentrine (1),"press_release | Ligand Reports Second Quarter 2020 Financial Results :: Ligand Pharmaceuticals Incorporated (LGND) | ... several partners also had significant regulatory, financing and business updates during the second quarter including verona pharma confirming with the fda its phase 3 plans for its nebulized <span style=""background-color: #FFFF00"">ensifentrine</span>.",NA,"http://52.23.161.54/redirect/yoann.randriamihaja/Press%20releases!!!html!!!03-08-2020!!!Ligand%20Pharmaceuticals,%20Inc._PR1_03-08-2020.html"">Ligand Reports Second Quarter 2020 Financial Results :: Ligand Pharmaceuticals Incorporated (LGND)"
